Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany

Peter Mohr, Emilie Scherrer, Chalid Assaf, Marc Bender, Carola Berking, Sheenu Chandwani, Thomas Eigentler, Imke Grimmelmann, Ralf Gutzmer, Sebastian Haferkamp, Jessica C. Hassel, Axel Hauschild, Rudolf Herbst, Ruixuan Jiang, Katharina C. Kähler, Clemens Krepler, Alexander Kreuter, Ulrike Leiter, Carmen Loquai, Friedegund MeierClaudia Pföhler, Anja Rudolph, Dirk Schadendorf, Maximo Schiavone, Gaston Schley, Patrick Terheyden, Selma Ugurel, Jens Ulrich, Jochen Utikal, Carsten Weishaupt, Julia Welzel, Michael Weichenthal*

*Corresponding author for this work
3 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry